The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지

Drug Interaction between Proton Pump Inhibitors and Clopidogrel: Safe Perspective

항혈소판제제를 포함한 약물상호작용에 미치는 프로톤펌프억제제의 영향: Safe 측면

  • Jo, Yun-Ju (Department of Internal Medicine, Eulji University School of Medicine)
  • 조윤주 (을지대학교 의과대학 내과학교실)
  • Published : 2011.07.01
⟨ Previous Next ⟩

Abstract

Clopidogrel prevent atherothrombotic complications following acute coronary syndromes by inhibiting platelet aggregation. However, in case of concomitant use of clopidogrel and proton pump inhibitor (PPI) for prophylaxis of gastrointestinal (GI) bleeding, the anti-clotting of clopidogrel will be decreased because PPI inhibit competitively cytochrome P450 enzymes, especially CYP2C19. Through several pharmacodynomic studies, omeprazole, but not other PPIs, worsens surrogate markers (e.g., platelet reactivity index) of clopidogrel efficacy. And many observational studies show concomitant use of clopidogrel and PPI have increased the risks of cardiovascular (CV) events (hazard/odds ratios = 1.25-1.5). However, only one prospective randomized trial (COGENT trial) of omeprazole vs. placebo in clopidogrel users show no difference in CV events (hazard ratio = 1.02) and decrease the risk of GI bleeding (hazard ratio = 0.13). Further well designed research will need to determine whether a pharmacodynamic effect of clopidogrel affected by PPI will be changed clinical CV events. Clinical decisions about concomitant use of PPI and clopidogrel must be balance overall risks and benefits, considering both CV and GI complications.

Keywords

References

  1. U.S. Food and Drug Administration. FDA announces new warning on plavix: avoid use with Prilosec/Prilosec OTC [Internet]. [cited 2009 Nov 18]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm191169.htm
  2. Li XQ, Andersson TB, Ahlstrom M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004;32:821-827. https://doi.org/10.1124/dmd.32.8.821
  3. Beitelshees AL, McLeod HL. Clopidogrel pharmacogenetics: promising steps towards patient care? Arterioscler Thromb Vasc Biol 2006;26:1681-1683. https://doi.org/10.1161/01.ATV.0000232583.51472.73
  4. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354-362. https://doi.org/10.1056/NEJMoa0809171
  5. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360:363-375. https://doi.org/10.1056/NEJMoa0808227
  6. Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002;41:913-958. https://doi.org/10.2165/00003088-200241120-00002
  7. Gilard M, Arnaud B, Le Gal G, Abgrall JF, Boschat J. Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost 2006;4:2508-2509. https://doi.org/10.1111/j.1538-7836.2006.02162.x
  8. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008;51:256-260. https://doi.org/10.1016/j.jacc.2007.06.064
  9. Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 2008;48:475-484. https://doi.org/10.1177/0091270008315310
  10. Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009;157:148.e1-5. https://doi.org/10.1016/j.ahj.2008.09.017
  11. Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009;101:714-719.
  12. O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomized trials. Lancet 2009;374:989-997. https://doi.org/10.1016/S0140-6736(09)61525-7
  13. Lanas A, García-Rodríguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclooxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006;55:1731-1738. https://doi.org/10.1136/gut.2005.080754
  14. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502. https://doi.org/10.1056/NEJMoa010746
  15. Connolly SJ, Pogue J, Hart RG, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009;360:2066-2078. https://doi.org/10.1056/NEJMoa0901301
  16. Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol 2007;102:507-515. https://doi.org/10.1111/j.1572-0241.2006.01062.x
  17. Yeomans N, Lanas A, Labenz J, et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol 2008;103:2465-2473. https://doi.org/10.1111/j.1572-0241.2008.01995.x
  18. Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol 2010;105:2533-2549. https://doi.org/10.1038/ajg.2010.445
  19. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010;363:1909-1917. https://doi.org/10.1056/NEJMoa1007964
  20. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009;180:713-718. https://doi.org/10.1503/cmaj.082001
  21. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009;301:937-944. https://doi.org/10.1001/jama.2009.261
  22. Kreutz RP, Stanek EJ, Aubert R, et al. Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the Clopidogrel Medco Outcomes Study. Pharmacotherapy 2010;30:787-796. https://doi.org/10.1592/phco.30.8.787
  23. Aronow HD, Steinhubl SR, Brennan DM, Berger PB, Topol EJ. Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) Trial. Am Heart J 2009;157:369-374. https://doi.org/10.1016/j.ahj.2008.09.011
  24. Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a Cohort Study. Lancet 2009;373:309-317. https://doi.org/10.1016/S0140-6736(08)61845-0
  25. Ray WA, Murray KT, Griffin MR, et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a Cohort Study. Ann Intern Med 2010;152:337-345. https://doi.org/10.7326/0003-4819-152-6-201003160-00003
  26. Charlot M, Ahlehoff O, Norgaard ML, et al. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a Nationwide Cohort Study. Ann Intern Med 2010;153:378-386. https://doi.org/10.7326/0003-4819-153-6-201009210-00005
  27. van Boxel OS, van Oijen MG, Hagenaars MP, Smout AJ, Siersema PD. Cardiovascular and gastrointestinal outcomes in clopidogrel users on proton pump inhibitors: results of a large Dutch Cohort Study. Am J Gastroenterol 2010;105:2430-2436, quiz 2437. https://doi.org/10.1038/ajg.2010.334
  28. Banerjee S, Weideman RA, Weideman MW, et al. Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention. Am J Cardiol 2011;107:871-878. https://doi.org/10.1016/j.amjcard.2010.10.073
  29. Kim WH, Hong SP, Kim YH, et al. Effect of proton pump inhibitor and clopidogrel combination on the outcome of patients with ischemic heart disease. Korean J Med 2011;80:434-442.
  30. Lima JP, Brophy JM. The potential interaction between clopidogrel and proton pump inhibitors: a systematic review. BMC Med 2010;8:81. https://doi.org/10.1186/1741-7015-8-81
  31. Siller-Matula JM, Jilma B, Schrör K, Christ G, Huber K. Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis. J Thromb Haemost 2010;8:2624-2641, doi: 10.1111/j.1538-7836.2010.04049.X.
  32. U.S. Food and Drug Administration. FDA reminder to avoid concomitant use of plavix (clopidoregl) and omeprazle [Internet]. [cited 2010 Oct 27]. Available from: www.fda.gov/Drugs/DrugSafety/ucm231161.htm
  33. Laine L, Hennekens C. Proton pump inhibitor and clopidogrel interaction: fact or fiction? Am J Gastroenterol 2010;105:34-41. https://doi.org/10.1038/ajg.2009.638
  34. Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007;5:2429-2436. https://doi.org/10.1111/j.1538-7836.2007.02775.x